
Research and development of gene therapy medicines for the treatment of rare diseases.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: January 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Orphan Europe
B
Development and commercialization of drugs for rare diseases.
AstraZeneca
B
Research, development, production, and marketing of prescription medicines in five therapeutic areas: cardiovascular, renal & metabolism, oncology, respiratory & immunology, rare diseases, and vaccines and immune therapies.
GlaxoSmithKline France
A
Research and development of pharmaceuticals in respiratory, immunological, inflammatory diseases, oncology, HIV, and infectious diseases.
Initiatives identified among leaders
Réduction des émissions de gaz à effet de serre
“GlaxoSmithKline France a pour objectif de réduire ...” - GlaxoSmithKline FranceRenforcement des systèmes de santé
“AstraZeneca renforce les systèmes de santé en part...” - AstraZenecaAméliorer l'accès aux soins
“Orphan Europe améliore l'accès aux soins en dévelo...” - Orphan Europe50% of similar organizations communicate on CSR issues
+542 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports